Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6 [0.03%]
EPCORITAMAB单药治疗复发/难治性弥漫大B细胞淋巴瘤的门诊患者：EPCORE NHL-6中期研究结果
David Andorsky,Adelba Torres Lopez,Rakhee Vaidya et al.
David Andorsky et al.
Background: Epcoritamab, a CD3 × CD20 bispecific antibody approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), is administered subcutaneously with recommended 24 hours inpatient monitoring after the fi...
Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis [0.03%]
达沙替尼50毫克每天治疗患者的疗效：汇总分析
Fadi G Haddad,Elias Jabbour,Koji Sasaki et al.
Fadi G Haddad et al.
Background: Dasatinib is approved at 100 mg/d for newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). We report outcomes with frontline dasatinib 50 mg/d in a large cohort of patients with CML-CP. ...
Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma [0.03%]
皮细胞T细胞淋巴瘤患者系统治疗和全身皮肤电子线照射联合使用的安全性研究
Jonathan A Baron,Leah Cohen,Monica Chelius et al.
Jonathan A Baron et al.
Purpose: To evaluate the safety and outcomes of total skin electron therapy (TSET) delivered with concurrent systemic therapy (CS) for cutaneous T-cell lymphoma (CTCL). ...
Reversing Transplant Ineligibility With Teclistamab in Ultra-High-Risk Relapsed/Refractory Multiple Myeloma With Extramedullary Disease [0.03%]
Teclistamab逆转超高危复发/难治性伴髓外多发性骨髓瘤患者移植禁忌症
Rudra Narayan Swain,Sarthak Wadhera,Aditya Jandial et al.
Rudra Narayan Swain et al.
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study [0.03%]
异基因干细胞移植后复发的急性髓系白血病和骨髓增生异常综合征的治疗：GITMO AML/MDS-Relapse 注册研究深入分析
Michele Malagola,Domenica Matranga,Luca Castagna et al.
Michele Malagola et al.
Background: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse is the most frequent cause of allogeneic stem cell transplantation (allo-SCT) failure. The utility of post-relapse therapy is controversi...
SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell Lymphoma [0.03%]
SOHO最新研究及下一步问题｜优化外周T细胞淋巴瘤的一线治疗
Neha Akkad,Neha Mehta-Shah
Neha Akkad
Nodal PTCLs are a rare subset of non-Hodgkin lymphomas that are clinically and biologically heterogenous and have poor outcomes. There have been several attempts to improve upon existing frontline therapies, many of which have shown improve...
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence, Challenges, and Opportunities for Cure [0.03%]
神州细胞治疗药物的研发进展和未来方向 | 复发/难治弥漫性大B细胞淋巴瘤的个体化诊疗：证据、挑战与治愈机遇
Jacqueline F Wang,Gilles Salles,Efrat Luttwak
Jacqueline F Wang
The therapeutic landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has rapidly evolved over the past decade with the introduction of multiple novel agents and the emergence of immunotherapies such as bispecific ...
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1 [0.03%]
一项关于新型JAK抑制剂Momelotinib对比Ruxolitinib在贫血的初治原发性骨髓纤维化患者中的脾脏体积缩小和减少输血依赖及对无劣效影响的Ⅲ期临床研究（SIMPLIFY-1）
Francesca Palandri,Nicolaas P M Schaap,Jerome Rey et al.
Francesca Palandri et al.
Introduction: Improvements in splenomegaly, anemia, and overall survival (OS) are key considerations in the management of patients with myelofibrosis. In the phase III SIMPLIFY-1 trial (NCT01969838), momelotinib was nonin...
Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study [0.03%]
奥雷巴替尼治疗慢性髓性白血病淋巴细胞急变期或费城染色体阳性难治复发急性淋巴细胞白血病的疗效：一项多中心回顾性研究
Mei Bao,Jian Huang,Zongru Li et al.
Mei Bao et al.
Objectives: To explore the efficacy and safety olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase (CML-LBP) or relapsed or refractory Philadelphia chromosome-positiv...
Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017 [0.03%]
在中东急性髓系白血病队列中验证欧洲白血病网2022年指南：与生存结局的相关性及与ELN 2017年的比较
Salem H Alshemmari,Ahmad AlSarraf,Reem Ameen et al.
Salem H Alshemmari et al.
Background: The European LeukemiaNet (ELN) guidelines are widely used for risk stratification in acutemyeloid leukemia (AML), but validation in non Western patients remains limited. ...